MedTrace Logo

Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

NCT04393805 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 744

Last updated 2021-03-18

No results posted yet for this study

Summary

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

Conditions

Interventions

DRUG

Low Molecular Weight Heparin

Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin

Sponsors & Collaborators

  • University of Padova

    collaborator OTHER

  • Quovadis Associazione

    lead OTHER

Principal Investigators

  • Paolo Simioni, Prof. · Department of Medicine, University of Padua (I)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-02-26
Completion
2021-02-26
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04393805 on ClinicalTrials.gov